Amendments to the Claims

This listing of claims replaces all prior versions, and listings, of claims in the above-identified application:

1-20. **canceled**

2 ~~21.~~ 1 **(previously presented)** The method of Claim ~~29~~ wherein the CGRP receptor is on a cell.

7 ~~22.~~ 6 **(previously presented)** The method of Claim ~~29~~ wherein the CGRP receptor is cell free.

3 ~~23.~~ 2 **(original)** The method of Claim ~~21~~ wherein the cell is in culture.

4 ~~24.~~ 2 **(original)** The method of Claim ~~21~~ wherein the cell is part of a tissue.

5 ~~25.~~ 2 **(original)** The method of Claim ~~21~~ wherein the cell is in an animal.

6 ~~26.~~ 5 **(original)** The method of Claim ~~25~~ wherein the animal is a human.

27-28. **canceled**

1 ~~29.~~ **(previously presented)** A method for inhibiting CGRP binding to one or more CGRP receptors comprising contacting a CGRP receptor with a composition comprising a peptide having the general formula:

$$R^1\text{-}X\text{-}Z$$

wherein Z is a CGRP receptor-binding peptide, R^1 is an organic group, X is



and wherein R^2 and R^3 are independently H or an organic group and n is a whole integer between 1 and 10;
in an amount effective to inhibit CGRP binding to one or more CGRP receptors.

8 ~~30.~~ **(original)** The method of Claim ~~29~~ 1 wherein Z is a peptide fragment of at least 15 amino acids from CGRP.

9 ~~31.~~ **(original)** The method of Claim ~~30~~ 8 wherein Z comprises the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.

10 ~~32.~~ **(previously presented)** The method of Claim ~~29~~ 1 wherein Z is an antagonist of human CGRP.

11 ~~33.~~ **(previously presented)** The method of Claim ~~29~~ 1 wherein Z is an antagonist of α-CGRP or β-CGRP.

12 ~~34.~~ **(currently amended)** The method of Claim ~~33~~ 11 wherein Z comprises ~~the~~ an amino acid sequence selected from the group consisting of SEQ ID NOS:6-17 and 23.

13 ~~35.~~ **(currently amended)** The method of Claim ~~33~~ 11 wherein Z comprises ~~the~~ an amino acid sequence selected from the group consisting of SEQ ID NOS:18-22.

14 ~~36.~~ **(original)** The method of claim ~~29~~ 1 wherein Z is a CGRP antagonist peptide fragment selected from the group consisting of amylin, CGRP and adrenomedullin.

15 ~~37.~~ **(original)** The method of Claim ~~29~~ 1 wherein R^1 is an aromatic group, a heterocyclic group or an alkyl group and R^2 and R^3 are independently H, an aromatic group or an alkyl group.

16 ~~38.~~ **(original)** The method of Claim ~~37~~ 15 wherein R^1 is a C1-C4 alkyl group.

17 ~~39.~~ **(original)** The method of Claim ~~38~~ 16 wherein R^1 is a fluoroalkyl.

18 ~~40.~~ **(original)** The method of Claim ~~38~~ 16 wherein R^2 and R^3 are independently H, a C1-C4 alkyl group or a phenyl moiety.

19 ~~41.~~ **(original)** The method of Claim ~~38~~ 16 wherein R^1 is a C5-C10 aromatic group, a C5-C9 heterocyclic group or a C1-C4 alkyl group.

20 42. **(original)** The method of Claim ~~41~~ 19 wherein R^2 and R^3 are independently H or a C5-C10 aromatic group or a C1-C4 alkyl group.

21 ~~43.~~ **(original)** The method of Claim ~~37~~ 15 wherein R^1 has the general formula:



and wherein R^4-R^8 are each independently selected from the group of H, fluoro, chloro, bromo, iodo, nitro, nitrile (cyano), amino, N-methyl amino, N,N-dimethyl amino, hydroxy, methoxy, thiomethoxy (S-methyl), methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, trifluoromethyl, trifluoromethoxy, vinyl, acetamido, phenyl, toluyl, and methoxyphenyl.

~~44.~~ 21 **(original)** The method of Claim ~~43~~ wherein R^6 is trifluoromethyl and R^4, R^5, R^7 and R^8 are F.

~~45.~~ 24 **(previously presented)** The method of Claim ~~37~~ 15 wherein R^1 is



and wherein Y is selected from the group consisting of O, NH, and S.

~~46.~~ 23 **(previously presented)** The method of Claim ~~43~~ 21 wherein the peptide is a CGRP antagonist having at least 15 consecutive amino acids selected from a protein from the group consisting of N-α-benzoyl-α-CGRP, N-α-benzyl-β-CGRP, N-α-benzoyl-β-CGRP and N-α-benzyl-α CGRP, dibenzyl-h-α-CGRP and dibenzyl-h-β-CGRP.

25 ~~47.~~ **(original)** The method of Claim ~~37~~ 15 wherein R^1 is selected from the group consisting of:



and wherein X is selected from the group consisting of C and N.

48-53. **canceled**

26 ~~54.~~ **(previously presented)** The method of claim ~~29~~ 6 wherein Z is a vasoactive peptide.

27 ~~55.~~ **(previously presented)** The method of claim ~~54~~ 26 wherein Z is an antagonist of human CGRP.